These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 24083979)

  • 1. MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations.
    Kuster DW; Mulders J; Ten Cate FJ; Michels M; Dos Remedios CG; da Costa Martins PA; van der Velden J; Oudejans CB
    J Mol Cell Cardiol; 2013 Dec; 65():59-66. PubMed ID: 24083979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
    Van Driest SL; Vasile VC; Ommen SR; Will ML; Tajik AJ; Gersh BJ; Ackerman MJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1903-10. PubMed ID: 15519027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene.
    Cardim N; Perrot A; Santos S; Morgado P; Pádua M; Ferreira S; Reis RP; Monteiro C; Ferreira T; Correia JM; Osterziel KJ
    Rev Port Cardiol; 2005 Dec; 24(12):1463-76. PubMed ID: 16566405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy.
    Girolami F; Olivotto I; Passerini I; Zachara E; Nistri S; Re F; Fantini S; Baldini K; Torricelli F; Cecchi F
    J Cardiovasc Med (Hagerstown); 2006 Aug; 7(8):601-7. PubMed ID: 16858239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland.
    Jääskeläinen P; Kuusisto J; Miettinen R; Kärkkäinen P; Kärkkäinen S; Heikkinen S; Peltola P; Pihlajamäki J; Vauhkonen I; Laakso M
    J Mol Med (Berl); 2002 Jul; 80(7):412-22. PubMed ID: 12110947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic diagnosis of hypertrophic cardiomyopathy using mass spectrometry DNA arrays and high resolution melting.
    Santos S; Lança V; Oliveira H; Branco P; Silveira L; Marques V; Brito D; Madeira H; Bicho M; Fernandes AR
    Rev Port Cardiol; 2011 Jan; 30(1):7-18. PubMed ID: 21425739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations.
    Sequeira V; Wijnker PJ; Nijenkamp LL; Kuster DW; Najafi A; Witjas-Paalberends ER; Regan JA; Boontje N; Ten Cate FJ; Germans T; Carrier L; Sadayappan S; van Slegtenhorst MA; Zaremba R; Foster DB; Murphy AM; Poggesi C; Dos Remedios C; Stienen GJ; Ho CY; Michels M; van der Velden J
    Circ Res; 2013 May; 112(11):1491-505. PubMed ID: 23508784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy.
    Richard P; Isnard R; Carrier L; Dubourg O; Donatien Y; Mathieu B; Bonne G; Gary F; Charron P; Hagege M; Komajda M; Schwartz K; Hainque B
    J Med Genet; 1999 Jul; 36(7):542-5. PubMed ID: 10424815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy.
    O'Leary TS; Snyder J; Sadayappan S; Day SM; Previs MJ
    J Mol Cell Cardiol; 2019 Feb; 127():165-173. PubMed ID: 30550750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
    Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
    J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
    Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
    Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of Autophagy Ameliorates Cardiomyopathy in
    Singh SR; Zech ATL; Geertz B; Reischmann-Düsener S; Osinska H; Prondzynski M; Krämer E; Meng Q; Redwood C; van der Velden J; Robbins J; Schlossarek S; Carrier L
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29021349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation.
    Adalsteinsdottir B; Teekakirikul P; Maron BJ; Burke MA; Gudbjartsson DF; Holm H; Stefansson K; DePalma SR; Mazaika E; McDonough B; Danielsen R; Seidman JG; Seidman CE; Gunnarsson GT
    Circulation; 2014 Sep; 130(14):1158-67. PubMed ID: 25078086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel MYBPC3 gene variant in a patient with hypertrophic cardiomyopathy.
    Brion M; Allegue C; Gil R; Blanco-Verea A; Carracedo A; Pagannone E; Evangelista A; Di Castro S; Marchitti S; Stanzione R; Volpe M; Rubattu S
    Ann Clin Lab Sci; 2010; 40(3):285-9. PubMed ID: 20689143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micro-exons of the cardiac myosin binding protein C gene: flanking introns contain a disproportionately large number of hypertrophic cardiomyopathy mutations.
    Frank-Hansen R; Page SP; Syrris P; McKenna WJ; Christiansen M; Andersen PS
    Eur J Hum Genet; 2008 Sep; 16(9):1062-9. PubMed ID: 18337725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy.
    Meurs KM; Sanchez X; David RM; Bowles NE; Towbin JA; Reiser PJ; Kittleson JA; Munro MJ; Dryburgh K; Macdonald KA; Kittleson MD
    Hum Mol Genet; 2005 Dec; 14(23):3587-93. PubMed ID: 16236761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.
    van Dijk SJ; Paalberends ER; Najafi A; Michels M; Sadayappan S; Carrier L; Boontje NM; Kuster DW; van Slegtenhorst M; Dooijes D; dos Remedios C; ten Cate FJ; Stienen GJ; van der Velden J
    Circ Heart Fail; 2012 Jan; 5(1):36-46. PubMed ID: 22178992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features of dilated cardiomyopathy-like hypertrophic cardiomyopathy caused by a 13261 G > A mutation in cardiac myosin-binding protein C gene].
    Wang SX; Zou YB; Fu CY; Wang H; Wang JZ; Song XD; Chen JZ; Hui RT
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Jan; 35(1):17-20. PubMed ID: 17386157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA expression profiles in familial hypertrophic cardiomyopathy with myosin-binding protein C3 (MYBPC3) gene mutations.
    Lin LR; Hu XQ; Lu LH; Dai JZ; Lin NN; Wang RH; Xie ZX; Chen XM
    BMC Cardiovasc Disord; 2022 Jun; 22(1):278. PubMed ID: 35717150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
    Calore C; De Bortoli M; Romualdi C; Lorenzon A; Angelini A; Basso C; Thiene G; Iliceto S; Rampazzo A; Melacini P
    J Med Genet; 2015 May; 52(5):338-47. PubMed ID: 25740977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.